2014
Genotype and risk of major bleeding during warfarin treatment
Kawai V, Cunningham A, Vear S, Van Driest S, Oginni A, Xu H, Jiang M, Li C, Denny J, Shaffer C, Bowton E, Gage B, Ray W, Roden D, Stein C. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 2014, 15: 1973-1983. PMID: 25521356, PMCID: PMC4304738, DOI: 10.2217/pgs.14.153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiological Specimen BanksCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P450 Family 4Dose-Response Relationship, DrugEthnicityFemaleGene FrequencyGenetic Association StudiesGenetic VariationGenotypeHemorrhageHumansMaleMiddle AgedRisk FactorsVitamin K Epoxide ReductasesWarfarin
2012
Predicting warfarin dosage in EuropeanAmericans and AfricanAmericans using DNA samples linked to an electronic health record
Ramirez A, Shi Y, Schildcrout J, Delaney J, Xu H, Oetjens M, Zuvich R, Basford M, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley J, Ritchie M, Masys D, Roden D, Crawford D, Denny J. Predicting warfarin dosage in EuropeanAmericans and AfricanAmericans using DNA samples linked to an electronic health record. Pharmacogenomics 2012, 13: 407-418. PMID: 22329724, PMCID: PMC3361510, DOI: 10.2217/pgs.11.164.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overAnticoagulantsAryl Hydrocarbon HydroxylasesBlack or African AmericanCalcium-Binding ProteinsCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P450 Family 4Dose-Response Relationship, DrugDrug Administration ScheduleElectronic Health RecordsFemaleHumansMaleMiddle AgedMixed Function OxygenasesPolymorphism, Single NucleotideSubstance-Related DisordersVitamin K Epoxide ReductasesWarfarinWhite People